Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

LMTX

- PMLiVE

FDA approves Alzheimer’s diagnostic drug

GE Healthcare's Vizamyl to compete with Lilly's Amyvid

- PMLiVE

Lundbeck and Otsuka take Alzheimer’s drug into phase III

Lu AE58054 affects levels of serotonin in the brain

- PMLiVE

Novo backs Victoza’s prospects in Alzheimer’s

Chief science officer says phase III trial could begin in three years

- PMLiVE

US NIH provides $45m for Alzheimer’s research

Projects will investigate basic science of the neurological condition

- PMLiVE

Novo Nordisk’s Victoza shows Alzheimer’s benefits

UK scientists say the diabetes drug could reverse effects of dementia

- PMLiVE

Alzheimer’s disease pipeline takes multiple hits

Following a number of recent failures of clinical compounds, researchers are shifting the focus from late-stage disease to early-stage or prophylactic therapies

- PMLiVE

AbbVie sales jump on strong Humira gains

Extra indications help boost performance of treatment for autoimmune disorders

- PMLiVE

FDA panel fails to back new use for AbbVie’s Humira

Votes 12 to 1 against new use in spondyloarthritis

- PMLiVE

FDA fast-tracks Elan’s Alzheimer’s drug

Speeds up regulatory process for ELND005 for the treatment of neuropsychiatric symptoms

- PMLiVE

Merck maintains lead in BACE inhibitors for Alzheimer’s

Positive results in phase Ib study in patients with Alzheimer’s disease

- PMLiVE

AbbVie: UK patients want better arthritis care

Study from Humira manufacturer concludes that UK doctors need better collaboration with patients

- PMLiVE

Elotuzumab on track for multiple myeloma

BMS and AbbVie present phase II results at European Haematology Association meeting

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links